Publications by authors named "Mark Danese"

Claim this Profile
I
Imaging Utilization and Treatment Patterns of Brain Metastases in Patients With Non-Small Cell Lung Cancer: A SEER-Medicare and SEER Database Analysis.
Mark D Danese, Jason Shafrin, Melissa Laurie, Beata Korytowsky, Shane Jordan

Clin Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of chemotherapy and surgery timing on mortality in upper and lower extremity osteosarcoma.
Mark D Danese, John S Groundland

J Natl Cancer Inst· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Liu, Xiao, Liu, et al.
Mark D Danese, John S Groundland

J Natl Cancer Inst· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of factor Xa inhibitor-related traumatic non-intracranial bleeding events with andexanet alfa or four-factor prothrombin complex concentrate in a US multicenter observational study.
Paul P Dobesh, Craig I Coleman, Mark Danese, Eva Lesén, Raymond C Chang

J Am Coll Emerg Physicians Open· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Trial of the Impact of Ferric Citrate on Erythropoietin and Intravenous Iron Use in Patients Receiving Dialysis.
Geoffrey A Block, Mohammed Reza Mizani, Varshasb Broumand, F David Newby, Ayodele Erinle, Mark Danese

Am J Nephrol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of an algorithm to identify small cell lung cancer patients in claims databases.
Mark D Danese, Akhila Balasubramanian, D Gwyn Bebb, Xerxes Pundole

Front Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to "Letter to Dobesh et al. on lower mortality with andexanet alfa in factor Xa inhibitor-related major bleeding".
Paul P Dobesh, Gregory J Fermann, Mary J Christoph, Bruce Koch, Eva Lesén, Mark Danese, Sherry Danese

Res Pract Thromb Haemost· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hereditary Angioedema With Normal C1 Inhibitor: US Survey of Prevalence and Provider Practice Patterns.
Marc A Riedl, Mark Danese, Sherry Danese, Julie Ulloa, Andreas Maetzel

J Allergy Clin Immunol Pract· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study.
Paul P Dobesh, Gregory J Fermann, Mary J Christoph, Bruce Koch, Eva Lesén, Mark Danese, Sherry Danese

Res Pract Thromb Haemost· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Patterns and Survival in Locally Advanced or Metastatic Biliary Tract Cancer Using SEER Medicare Data.
Mark D Danese, Kabir Mody, Ramya Thota, Stacie C Lindsey, Melinda Bachini

Gastro Hep Adv· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data.
Mark D Danese, Melinda Daumont, Esmond Nwokeji, Michelle Gleeson, John R Penrod

Cancer Rep (Hoboken)· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Granulocyte Colony-Stimulating Factor (G-CSF) Use and Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Among Elderly Patients with Breast, Lung, or Prostate Cancer.
Mark D Danese, Jennifer Schenfeld, Jaime Shaw, Prasad Gawade, Akhila Balasubramanian

Adv Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The rate, cost and outcomes of parathyroidectomy in the united states dialysis population from 2016-2018.
Mark D Danese, Kathleen M Fox, Jennifer L Duryea, Pooja Desai, Robert J Rubin

BMC Nephrol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal evaluation of treatment patterns, risk factors and outcomes in patients with cardiovascular disease treated with lipid-lowering therapy in the UK.
Mark Danese, Eduard Sidelnikov, Guillermo Villa, David Catterick, Mazhar Iqbal

BMJ Open· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes with second-line therapy in advanced esophageal squamous cell carcinoma using SEER-Medicare data.
Mark Danese, Joseph Gricar, Pranav Abraham

Future Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real World Use and Effects of Calcimimetics in Treating Mineral and Bone Disorder in Hemodialysis Patients.
Mark D Danese, Deborah Lubeck, Vasily Belozeroff, Tzu-Chieh Lin, Pooja Desai

Am J Nephrol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer.
Joshua A Roth, Yong Yuan, Megan Othus, Mark Danese, Samuel Wagner

J Med Econ· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimation of the increased risk associated with recurrent events or polyvascular atherosclerotic cardiovascular disease in the United Kingdom.
Mark D Danese, Peter Pemberton-Ross, David Catterick, Guillermo Villa

Eur J Prev Cardiol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fibroblast growth factor 23 as a risk factor for cardiovascular events and mortality in patients in the EVOLVE trial.
Geoffrey A Block, Glenn M Chertow, Kerry Cooper, Shan Xing, Bruno Fouqueray, Mark D Danese

Hemodial Int· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diabetic Population-Based Model to Estimate Impact of Ranibizumab on Diabetic Retinopathy Severity in Patients with Diabetic Macular Edema.
Rohit Varma, Neil M Bressler, Quan V Doan, Ivan J Suñer, Mark Danese

Clin Ophthalmol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease.
Deborah Lubeck, Irene Agodoa, Nickhill Bhakta, Mark Danese, Kartik Pappu

JAMA Netw Open· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns, survival, and hospitalization in adult patients with acute lymphoblastic leukemia: an observational cohort study using SEER Medicare data.
Mark D Danese, Aaron Katz, Karynsa Cetin, Victoria Chia, Michelle L Gleeson

Leuk Lymphoma· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Generalized Data Model for clinical research.
Mark D Danese, Marc Halperin, Jennifer Duryea, Ryan Duryea

BMC Med Inform Decis Mak· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe.
Kamlesh Khunti, Mark D Danese, Lucie Kutikova, David Catterick, Francisco Sorio-Vilela

JAMA Netw Open· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prevalence, low-density lipoprotein cholesterol levels, and treatment of patients at very high risk of cardiovascular events in the United Kingdom: a cross-sectional study.
Mark D Danese, Eduard Sidelnikov, Lucie Kutikova

Curr Med Res Opin· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis